EAM
KLRS

Erste Asset Management’s Kalaris Therapeutics KLRS Stock Holding History

Erste Asset Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-713
Closed -$216K – 573
2021
Q4 		$216K Hold
713
– – ﹤0.01% 488
2021
Q3 		$408K Hold
713
– – 0.01% 435
2021
Q2 		$319K Hold
713
– – 0.01% 449
2021
Q1 		$364K Hold
713
– – 0.01% 413
2020
Q4 		$607K Buy
+713
New +$549K 0.02% 372

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Erste Asset Management's KLRS Position: Q1 2022 in Review

Erste Asset Management sold out of Kalaris Therapeutics (KLRS) in Q1 2022, closing a stake of 713 shares — an estimated $216K sold.

Erste Asset Management first reported a position in KLRS in Q4 2020 and held it in 5 quarters. The position peaked at $607K in Q4 2020. 84 funds tracked by Wall St. Rank hold KLRS as of Q1 2022.

  • Erste Asset Management reported no remaining Kalaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Erste Asset Management sold 713 Kalaris Therapeutics shares in Q1 2022, an estimated $216K.
  • Erste Asset Management first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 5 quarters.
  • Erste Asset Management's Kalaris Therapeutics position peaked at $607K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2022.

Based on Erste Asset Management's 13F filing for Q1 2022, filed 25 Nov 2024.